Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis

被引：2

作者：

Santoni, Matteo ^{[1
]}

Conti, Alessandro ^{[2
]}

Buti, Sebastiano ^{[3
]}

Bersanelli, Melissa ^{[3
]}

Foghini, Laura ^{[1
]}

Piva, Francesco ^{[4
]}

Giulietti, Matteo ^{[4
]}

Lusuardi, Lukas ^{[5
]}

Battelli, Nicola ^{[1
]}

机构：

[1] Macerata Hosp, Oncol Unit, Via Santa Lucia 2, I-62100 Macerata, Italy

[2] Bressanone Brixen Hosp, Azienda Osped Alto Adige, I-39042 Brixen, Bozen, Italy

[3] Univ Hosp Parma, Via Gramsci 14, I-43126 Parma, Italy

[4] Polytech Univ Marche, Dept Specialist Clin & Odontostomatol Sci, Ancona, Italy

[5] Paracelsus Med Univ Salzburg, Dept Urol & Androl, Salzburg, Austria

来源：

IMMUNOTHERAPY | 2018年 / 10卷 / 15期

关键词：

cancer; fatigue; immunotherapy; meta-analysis; programmed cell death-1; METASTATIC UROTHELIAL CARCINOMA; NIVOLUMAB PLUS IPILIMUMAB; OPEN-LABEL; LUNG-CANCER; SINGLE-ARM; 1ST-LINE TREATMENT; CLINICAL ACTIVITY; CHECKMATE; 032; PEMBROLIZUMAB; MULTICENTER;

D O I：

10.2217/imt-2018-0067

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Aim: We aimed to assess the incidence and relative risk (RR) of fatigue in cancer patients treated with anti programmed cell death-1 (PD-1) and anti programmed cell death ligand-1 (PD-L1) agents. Patients & methods: Eligible studies were selected according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Incidence, RR and 95% CIs were calculated using random or fixed-effects models. Results: Thirty-eight studies were included in this analysis, with a total of 11,719 patients. The incidences were 23.4 and 2.1% for all- and high-grade fatigue, respectively. The highest incidence of high-grade fatigue was reported by the combination of nivolumab and ipilimumab. Overall RR of high-grade fatigue with anti-PD-1/PD-L1 compared with chemotherapy or targeted therapy was 0.48. Conclusion: Treatment with anti-PD-1/PD-L1 agents correlates with lower incidence and RR of fatigue compared with standard therapies.

引用

页码：1303 / 1314

页数：12

共 50 条

[1] Efficacy and safety of programmed cell death-1/programmed cell death ligand-1 inhibitors in advanced urothelial malignancy: A systematic review and meta-analysis
Pattanaik, Smita
Dey, Sumit
Jaiswal, Nishant
Rohilla, Rachna
Singh, Shrawan Kumar
Mandal, Arup Kumar
Mavuduru, Ravimohan Suryanarayan
INDIAN JOURNAL OF UROLOGY, 2019, 35 (02) : 101 - 115
[2] The incidence risk of programmed cell death-1/programmed cell death ligand 1 inhibitor-related alopecia for cancer patients A systematic review and meta-analysis
Li, Mingkai
Huang, Linlin
Ren, Xiuhong
Liu, Lixia
Shi, Qinghong
Liu, Ling
Wang, Xiao
Tian, Yuan
Yu, Lili
Mi, Fuli
MEDICINE, 2020, 99 (42) : E22555
[3] Recent advances of immunotherapy in lung cancer: anti-programmed cell death-1/programmed death ligand-1 antibodies
Yang, Lu-Lu
Wu, Yi-Long
LUNG CANCER MANAGEMENT, 2014, 3 (02) : 175 - 190
[4] The relationship between pneumonitis and programmed cell death-1/programmed cell death ligand 1 inhibitors among cancer patients A systematic review and meta-analysis
Xu, Dongmei
Liu, Hongmei
Xiang, Meiyi
Feng, Alei
Tian, Mei
Li, Donghua
Mao, Yantao
Zhang, Li
Zhang, Shuisheng
Tian, Yuan
MEDICINE, 2020, 99 (41)
[5] Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis
Niglio, Scot A.
Jia, Rachel
Ji, Jiayi
Ruder, Samuel
Patel, Vaibhav G.
Martini, Alberto
Sfakianos, John P.
Marqueen, Kathryn E.
Waingankar, Nikhil
Mehrazin, Reza
Wiklund, Peter
Oh, William K.
Mazumdar, Madhu
Ferket, Bart S.
Galsky, Matthew D.
EUROPEAN UROLOGY, 2019, 76 (06) : 782 - 789
[6] Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis
Mori, Keiichiro
Pradere, Benjamin
Quhal, Fahad
Katayama, Satoshi
Mostafaei, Hadi
Laukhtina, Ekaterina
Schuettfort, Victor M.
D'Andrea, David
Egawa, Shin
Bensalah, Karim
Schmidinger, Manuela
Powles, Thomas
Shariat, Shahrokh F.
CANCER TREATMENT REVIEWS, 2021, 99
[7] Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
Naidoo, Jarushka
Wang, Xuan
Woo, Kaitlin M.
Iyriboz, Tunc
Halpenny, Darragh
Cunningham, Jane
Chaft, Jamie E.
Segal, Neil H.
Callahan, Margaret K.
Lesokhin, Alexander M.
Rosenberg, Jonathan
Voss, Martin H.
Rudin, Charles M.
Rizvi, Hira
Hou, Xue
Rodriguez, Katherine
Albano, Melanie
Gordon, Ruth-Ann
Leduc, Charles
Rekhtman, Natasha
Harris, Bianca
Menzies, Alexander M.
Guminski, Alexander D.
Carlino, Matteo S.
Kong, Benjamin Y.
Wolchok, Jedd D.
Postow, Michael A.
Long, Georgina V.
Hellmann, Matthew D.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07) : 709 - +
[8] Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism
Jaafar, Jaafar
Fernandez, Eugenio
Alwan, Heba
Philippe, Jacques
ENDOCRINE CONNECTIONS, 2018, 7 (05): : R196 - R211
[9] Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials
Huang, Zilu
Zheng, Shuohan
Ding, Shirong
Wei, Yinghong
Chen, Chen
Liu, Xing
Li, He
Xia, Yunfei
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2021, 17 (03) : 676 - 687
[10] Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer A Systematic Review and Meta-analysis
Duan, Jianchun
Cui, Longgang
Zhao, Xiaochen
Bai, Hua
Cai, Shangli
Wang, Guoqiang
Zhao, Zhengyi
Zhao, Jing
Chen, Shiqing
Song, Jia
Qi, Chuang
Wang, Qing
Huang, Mengli
Zhang, Yuzi
Huang, Depei
Bai, Yuezong
Sun, Feng
Lee, J. Jack
Wang, Zhijie
Wang, Jie
JAMA ONCOLOGY, 2020, 6 (03) : 375 - 384

← 1 2 3 4 5 →